Table S1 from Camrelizumab Plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study

Yuanyuan Qu,Hailiang Zhang,Guo H,Hong Luo,Qing Zou,Nianzeng Xing,Shujie Xia,Zhongquan Sun,Xuepei Zhang,Chao‐Hong He,Jianguo Cai,Xiao Zhang,Quanren Wang,Dingwei Ye

DOI: https://doi.org/10.1158/1078-0432.22481628.v1

2023-01-01

Abstract:Serious treatment-related adverse events

What problem does this paper attempt to address?

Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study

Yuan-Yuan Qu,Hai-Liang Zhang,Hongqian Guo,Hong Luo,Qing Zou,Nianzeng Xing,Shujie Xia,Zhongquan Sun,Xuepei Zhang,Chaohong He,Jinling Cai,Xiao Zhang,Quanren Wang,Ding-Wei Ye

DOI: https://doi.org/10.1158/1078-0432.ccr-21-1698

IF: 13.801

2021-08-16

Clinical Cancer Research

Abstract:Abstract Purpose: Blockade of immune checkpoint and angiogenesis is an effective treatment strategy for advanced or metastatic renal cell carcinoma (RCC). We report the results of camrelizumab plus famitinib in the RCC cohort of an open-label, multicenter, phase II basket study. Patients and Methods: Eligible patients were enrolled to receive camrelizumab (200 mg i.v. every 3 weeks) and famitinib (20 mg orally once daily). Primary endpoint was objective response rate (ORR) per RECIST version 1.1. Results: Totally, 38 patients were recruited, including 13 (34.2%) treatment-naïve and 25 (65.8%) previously treated patients. With a median duration from enrollment to data cutoff of 16.5 months (range, 6.1–20.4), 23 patients achieved a confirmed objective response, and ORR was 60.5% [95% confidence interval (CI), 43.4–76.0]. Responses in 18 (78.3%) responders were still ongoing, and Kaplan–Meier estimated median duration of response had not been reached yet (range, 1.0+–14.8+ months). Median progression-free survival (PFS) was 14.6 months (95% CI, 6.2–not reached). ORR was 84.6% (95% CI, 54.6–98.1) in treatment-naïve patients and 48.0% (95% CI, 27.8–68.7) in pretreated patients; median PFS had not been reached and was 13.4 months (95% CI, 4.1–not reached), respectively. Most common grade 3 or 4 treatment-related adverse events included proteinuria (18.4%), hypertension (18.4%), decreased neutrophil count (13.2%), palmar-plantar erythrodysesthesia syndrome (10.5%), and hypertriglyceridemia (10.5%). No treatment-related deaths occurred, and no new safety signals were observed. Conclusions: Camrelizumab plus famitinib showed potent and enduring antitumor activity in patients with advanced or metastatic RCC, both in treatment-naïve and previously treated population.

oncology
Camrelizumab plus famitinib in patients with metastatic colorectal cancer: Results from an open-label, multicenter phase II basket study.

Tianshu Liu,Mudan Yang,Jin Li,Yueyin Pan,Ying Yuan,Shanyong Yi,Junsheng Wang,Ying Cheng,Jifeng Feng,Shegan Gao,Xicheng Wang,Song Qu,Xizhi Zhang,Jin Lu,Peng Xiu,Shuni Wang,Xinfeng Yang,Jia Fan

DOI: https://doi.org/10.1200/jco.2022.40.16_suppl.3577

IF: 45.3

2022-06-01

Journal of Clinical Oncology

Abstract:3577 Background: Dual blockade of immune checkpoint and angiogenesis is an effective strategy for multiple cancers. We initiated an open-label, multicenter phase II basket study to evaluate the antitumor activity and safety of camrelizumab (an anti-PD-1 antibody) plus famitinib (a receptor tyrosine kinase inhibitor) in patients (pts) with advanced solid tumors. Herein, we report the results from the metastatic colorectal cancer (mCRC) cohort. Methods: Pts with histologically confirmed mCRC, who had received previous irinotecan, oxaliplatin, and fluoropyrimidine combination chemotherapy, and progressed after ≥ 2 lines of systemic treatment were enrolled to receive camrelizumab (200 mg i.v. every 3 weeks) and famitinib (20 mg orally once daily). Primary endpoint was objective response rate (ORR) per RECIST version 1.1. Results: Between Jul 10, 2020, and Jul 12, 2021, of all the 44 mCRC pts enrolled, 14 (31.8%) pts had colon cancer (CC) and 30 (68.2%) pts had rectal cancer (RC). As of Nov 30, 2021, the median time from enrollment to data cutoff was 10.6 months (range, 4.7-16.7). The ORR was 13.6% (95% CI, 5.2-27.4) and the DCR was 45.5% (95% CI, 30.4-61.2) in all mCRC pts. Of them, no pts with CC achieved response; six pts with RC achieved PR, with the ORR of 20.0% (95% CI, 7.7-38.6) and the DCR of 46.7% (95% CI, 28.3-65.7). Pts with RC showed a median duration of response (DoR) of 7.1 months (95% CI, 2.3-not reached [NR]). The median overall survival (OS) was 15.2 months (95% CI, 7.2-NR) in pts with RC. Of all 44 mCRC pts, 28 (63.6%) had grade 3 or higher treatment related adverse events (TRAEs), mainly hypertension (25.0%), proteinuria (18.2%), decreased platelet count (11.4%), decreased neutrophil count (11.4%) and palmar-plantar erythrodysaesthesia syndrome (11.4%). Three (6.8%) pts discontinued any study treatment due to TRAEs. No grade 5 TRAE was reported. Conclusions: Camrelizumab plus famitinib appeared to show encouraging antitumor activity in pts with mCRC, especially in those with RC, and the safety profile of this combination regimen seemed to be manageable and consistent with single agent alone. Clinical trial information: NCT04346381. [Table: see text]

oncology
Camrelizumab Plus Famitinib Malate in Patients with Advanced Renal Cell Cancer and Unresectable Urothelial Carcinoma: A Multicenter, Open-Label, Single-Arm, Phase II Trial.

Yuan-Yuan Qu,Hongqian Guo,Hong Luo,Qing Zou,Ninazeng Xing,Zhongquan Sun,Xuepei Zhang,Shujie Xia,Chaohong He,Hailiang Zhang,Jinling Cai,Xiao Zhang,Quanren Wang,Dingwei Ye

DOI: https://doi.org/10.1200/jco.2020.38.15_suppl.5085

IF: 45.3

2020-01-01

Journal of Clinical Oncology

Abstract:5085 Background: Camrelizumab (SHR-1210) is a humanised anti-PD-1 antibody. Famitinib malate is a tyrosine kinase inhibitor (TKI) against VEGFR-2, PDGFR, c-kit, and FGFR. This is an ongoing, open label, multi-center Phase II study to assess the preliminary efficacy and safety of camrelizumab in combination with famitinib malate in patients (pts) with genitourinary cancers and gynecologic cancers. Here we just report genitourinary cancers results. Methods: Eligible pts were aged 18 or older, who had advanced clear-cell renal-cell carcinoma with their primary tumour resected or unresectable urothelial carcinoma, had an ECOG performance status of 0-1and measurable disease. Previous system treatments were allowed (excluding prior PD-1/PD-L1 inhibitors or famitinib treatment). Famitinib 20 mg was administered orally once daily with SHR-1210 200 mg given intravenously every 3 weeks. We assessed antitumour activity and safety in all pts who received at least one dose treatment. The primary end point was objective response rate (ORR) per RECIST v1.1. Results: From 23 Jan 2019 to 24 Jun2019, 35 pts were enrolled (25 with RCC, 10 with UC). Median previous treatment line was 1 (range, 1-4), and 50.0% of pts had received ≥2 prior therapies in RCC, all pts received one or more-line therapies in UC. At the data cut-off date (Dec 31, 2019), after at least 6 months follow-up, 22 (63%) pts were still receiving study treatment. The most common reason for discontinuing treatments was disease progression (n = 10). 16 pts achieved a confirmed response, all were partial response, with 8 additional > 24 weeks stable disease. the ORR was 52.0% (13/25, 95% CI 31.3% to 72.2%) in RCC and 30.0% (3/10) in UC, the disease control rate was 84.0% (21/25) in RCC and 70.0% in UC. 13/16 confirmed PR pts were still on treatment, the median duration of response is not reached. The most common grade 3-4 treatment-related AEs (TRAEs) were hypertension (17.1%), proteinuria (11.4%), platelet count decreased (8.6%), hand-foot syndrome (8.6%) and anemia (5.7%). Immune-related adverse events were observed in 7 pts (20%) of 35 pts, 1 pt (2.9%) with grade 3 enteritis. Conclusions: The camrelizumab with famitinib combination appeared to show encouraging activity in pts with heavy-treated RCC and UC, and the safety profile of the combination seemed to be manageable and consistent with that of each drug alone. This combination represented a novel potential treatment option for these settings and warranted further investigation. Clinical trial information: NCT03827837 .
Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study

Yuan-Yuan Qu,Zhongquan Sun,Weiqing Han,Qing Zou,Nianzeng Xing,Hong Luo,Xuepei Zhang,Chaohong He,Xiao-Jie Bian,Jinling Cai,Chunxia Chen,Quanren Wang,Ding-Wei Ye

DOI: https://doi.org/10.1136/jitc-2021-004427

IF: 12.469

2022-05-01

Journal for ImmunoTherapy of Cancer

Abstract:Background Dual blockade of immune checkpoint and angiogenesis is an effective strategy for multiple cancers. Camrelizumab is a monoclonal antibody against PD-1, and famitinib is a multitargeted receptor tyrosine kinase inhibitor with antiangiogenesis and antiproliferation activities against tumor cells. We conducted an open-label, multicenter phase 2 basket study of camrelizumab and famitinib in eight cohorts of genitourinary or gynecological cancers. Here, findings in cohort of advanced or metastatic urothelial carcinoma with platinum-progressive disease (cohort 2) are presented. Methods Patients who had progressed after platinum-based chemotherapy for advanced or metastatic disease or had progressed within 12 months after completion of platinum-based (neo)adjuvant therapy were given camrelizumab (200 mg intravenously every 3 weeks) plus famitinib (20 mg orally once daily). Primary endpoint was objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1. Results Totally, 36 patients were recruited. With a median duration from enrollment to data cut-off of 11.9 months (range 6.1–28.5), ORR was 30.6% (95% CI 16.3% to 48.1%). Median duration of response (DoR) was 6.3 months (95% CI 2.1 to not reached). Median progression-free survival (PFS) was 4.1 months (95% CI 2.2 to 8.2), and median overall survival (OS) was 12.9 months (95% CI 8.8 to not reached). Patients with bladder cancer (n=18) had numerically better outcomes, with an ORR of 38.9% (95% CI 17.3% to 64.3%) and a median PFS of 8.3 months (95% CI 4.1 to not reached). Median DoR and OS in this subpopulation had not been reached with lower limit of 95% CI of 4.2 months for DoR and 11.3 months for OS, respectively. Of 36 patients, 22 (61.1%) had grade 3 or 4 treatment-related adverse events, mainly decreased platelet count and hypertension. Conclusions Camrelizumab plus famitinib showed potent antitumor activity in advanced or metastatic urothelial carcinoma patients after platinum-based chemotherapy. Patients with bladder cancer seemed to have better response to this combination. Trial registration number NCT03827837 .

oncology,immunology
Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study

Zhou, Caicun

DOI: https://doi.org/10.1007/s00262-024-03715-4

IF: 6.63

2024-05-11

Cancer Immunology Immunotherapy

Abstract:The combination of immune checkpoint inhibitors and antiangiogenic agents has been effective in treating multiple cancers. This was further explored in an open-label, multicenter phase 2 basket study (NCT04346381), which evaluated the antitumor activity and safety of camrelizumab (an anti-PD-1 antibody) plus famitinib (a receptor tyrosine kinase inhibitor) in patients with advanced solid tumors. We herein report the findings from the cohort of advanced NSCLC patients who progressed after treatment with platinum-doublet chemotherapy and immunotherapy.

oncology,immunology
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter, Phase Ii Clinical Study of Famitinib in the Treatment of Advanced Metastatic Colorectal Cancer

Rui-Hua Xu,Lin Shen,Keming Wang,Gang Wu,Chunmei Shi,Kefeng Ding,Lizhu Lin,Jinwan Wang,Jianping Xiong,Changping Wu,Jin Li,Yunpeng Liu,Dong Wang,Yi Ba,Jueping Feng,Yuxian Bai,JingWang Bi,Liwen Ma,Jian Lei,Hao Yu

DOI: https://doi.org/10.1200/jco.2015.33.3_suppl.513

IF: 45.3

2015-01-01

Journal of Clinical Oncology

Abstract:513 Background: Colorectal cancer (CRC) is the third most frequently diagnosed cancer and is the fifth leading cause of cancer death in China. No standard care is available for patients with advanced CRC who failed the second-line treatment. Famitinib is a small-molecular, multi-target receptor tyrosine kinase inhibitor which primarily acts against angiogenesis. This phase II study was designed to evaluate the efficacy and safety of famitinib in the treatment of advanced colorectal cancer. Methods: This is a multi-center, randomized, double-blind, placebo-controlled, phase II clinical study (ClinicalTrials.gov Registration No.: NCT01762293). Totally 154 patients with advanced colorectal cancer who failed second or later-line treatments were randomized in a 2:1 ratio to receive either famitinib or placebo at 25 mg each day in each treatment cycle. The primary endpoint was progression-free survival (PFS), and the secondary endpoints include overall survival (OS), objective response rate (ORR), disease control rate (DCR), quality of life (QoL) and safety. The statistical analyses of endpoints were using intent-to-treat population. Results: Of 154 patients randomized, the mPFS was 2.8 and 1.5 months in the treatment group and control group, respectively (p=0.0034; HR=0.58). The ORR was 2.02% and 0.00% (p=0.54) and the DCR was 57.58% and 30.91% (p=0.0023) in the treatment group and control group, respectively. Analysis of OS data is ongoing. The frequently reported adverse events (AEs) include neutropenia, thrombocytopenia, hypertension, proteinuria, and hand-foot syndrome and were most grade 1/2. The incidences of serious adverse events (SAEs) for the famitinib and placebo groups were 11.11% and 9.09%, respectively (p=0.7884). Overall, famitinib was well tolerated and toxicities were manageable. Conclusions: Famitinib improved the PFS in patients with advanced metastatic colorectal cancer resulting in higher ORR and DCR in the treatment group with good safety and tolerability. Clinical trial information: NCT01762293.
A Multicenter Phase 2 Trial of Camrelizumab Plus Famitinib for Women with Recurrent or Metastatic Cervical Squamous Cell Carcinoma.

Lingfang Xia,Qi Zhou,Yunong Gao,Wenjing Hu,Ge Lou,Hong Sun,Jianqing Zhu,Jin Shu,Xianfeng Zhou,Rong Sun,Xiaohua Wu

DOI: https://doi.org/10.1038/s41467-022-35133-4

IF: 16.6

2022-01-01

Nature Communications

Abstract:This phase 2 study assesses the efficacy and safety of camrelizumab (an anti-PD-1 antibody) plus famitinib (anti-angiogenic agent) in women with pretreated recurrent or metastatic cervical cancer (ClinicalTrials.gov NCT03827837). Patients with histologically or cytologically confirmed cervical squamous cell carcinoma experiencing relapse or progression during or after 1–2 lines of systemic therapy for recurrent or metastatic disease are enrolled. Eligible patients receive camrelizumab 200 mg intravenously on day 1 of each 3-week cycle plus famitinib 20 mg orally once daily. The primary endpoint is the objective response rate. Secondary endpoints are duration of response, disease control rate, time to response, progression-free survival, overall survival, and safety. The trial has met pre-specified endpoint. Thirty-three patients are enrolled; median follow-up lasts for 13.6 months (interquartile range: 10.0–23.6). Objective responses are observed in 13 (39.4%, 95% confidence interval [CI]: 22.9–57.9) patients; the 12-month duration of response rate is 74.1% (95% CI: 39.1–90.9). Median progression-free survival is 10.3 months (95% CI: 3.5–not reached) and the 12-month overall survival rate is 77.7% (95% CI: 58.9–88.7). All patients experience treatment-related adverse events; grade ≥3 events occur in 26 (78.8%) patients. Treatment-related serious adverse events and deaths are observed in 9 (27.3%) and 2 (6.1%) patients, respectively. Camrelizumab plus famitinib shows promising antitumor activity with a manageable and tolerable safety profile in patients with pretreated recurrent or metastatic cervical squamous cell carcinoma. This combination may represent a treatment option for this population.
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A for Nonrandomized, Open-label, Phase II Trial

Jianming Xu,Jie Shen,Shanzhi Gu,Yun Zhang,Lihua Wu,Jian Wu,Guoliang Shao,Yanqiao Zhang,Li Xu,Tao Yin,Jingfeng Liu,Zhenggang Ren,Jianping Xiong,Xianhai Mao,Ling Zhang,Jiayin Yang,Lequn Li,Xiaoming Chen,Zhiming Wang,Kangsheng Gu,Xi Chen,Zhanyu Pan,Kuansheng Ma,Xinmin Zhou,Zujiang Yu,Enxiao Li,Guowen Yin,Xiao Zhang,Shuni Wang,Quanren Wang

DOI: https://doi.org/10.1158/1078-0432.CCR-20-2571

IF: 13.801

2021-01-01

Clinical Cancer Research

Abstract:Purpose: We assessed the efficacy and safety of camrelizumab [an anti-programmed death (PD-1) mAb] plus apatinib (a VEGFR-2 tyrosine kinase inhibitor) in patients with advanced hepatocellular carcinoma (HCC). Patients and Methods: This nonrandomized, open-label, multicenter, phase II study enrolled patients with advanced HCC who were treatment-naive or refractory/intolerant to first-line targeted therapy. Patients received intravenous camrelizumab 200 mg (for bodyweight >= 50 kg) or 3 mg/kg (for bodyweight <50 kg) every 2 weeks plus oral apatinib 250 mg daily. The primary endpoint was objective response rate (ORR) assessed by an independent review committee (IRC) per RECIST v1.1. Results: Seventy patients in the first-line setting and 120 patients in the second-line setting were enrolled. As of January 10, 2020, the RR was 34.3% [24/70; 95% confidence interval (CI), 23.3-46.61 in the first-line and 22.5% (27/120; 95% CI, 15.4-31.0) in the second-line cohort per IRC. Median progression-free survival in both cohorts was 5.7 months (95% CI, 5.4-7.4) and 5.5 months (95% CI, 3.7-5.6), respectively. The 12-month survival rate was 74.7% (95% CI, 62.5-83.5) and 68.2% (95% CI, 59.0-75.7), respectively. Grade >= 3 treatment-related adverse events (TRAE) were reported in 147 (77.4%) of 190 patients, with the most common being hypertension (34.2%). Serious TRAEs occurred in 55 (28.9%) patients. Two (1.1 %) treatment-related deaths occurred. Conclusions: Camrelizumab combined with apatinib showed promising efficacy and manageable safety in patients with advanced HCC in both the first-line and second-line setting. It might represent a novel treatment option for these patients.
Camrelizumab plus famitinib for advanced renal cell carcinoma or unresectable urothelial carcinoma: Updated results from a phase II trial.

Yuan-Yuan Qu,Qing Zou,Hongqian Guo,Nianzeng Xing,Zhongquan Sun,Weiqing Han,Hong Luo,Shujie Xia,Xuepei Zhang,Chaohong He,Hailiang Zhang,Jinling Cai,Xiao Zhang,Quanren Wang,Dingwei Ye

DOI: https://doi.org/10.1200/jco.2021.39.15_suppl.4550

IF: 45.3

2021-05-20

Journal of Clinical Oncology

Abstract:4550 Background: Considering the synergistic/additive effect of PD-1 blockade and angiogenesis inhibition, we conducted an open-label, multi-center phase II study of camrelizumab (an anti-PD-1 antibody) plus famitinib (a TKI against VEGFR-2, PDGFR, c-kit, and FGFR) in pts with heavily treated advanced renal cell carcinoma (RCC) and unresectable urothelial carcinoma (UC). Methods: Based on an adaptive two-stage design, 22 pts were enrolled in the RCC and UC cohort, respectively, at stage 1; if there were ≥7 responders of the 22 pts, enrollment would be extend to 33 at stage 2. Pts received famitinib 20 mg orally QD plus camrelizumab 200 mg IV Q3W. Primary endpoint was ORR per RECIST v1.1. Preliminary data at stage 1 were reported at ASCO 2020 annual meeting (#5085). More than 7 pts in each cohort had CR/PR during stage 1; enrollment of stage 2 had been completed, and the data are firstly reported here. Results: 74 pts (38 advanced RCC and 36 unresectable UC) were enrolled from Jan 23, 2019 to Dec 14, 2020. In RCC cohort, 65.8% of pts had received ≥1 prior VEGFR inhibitors. In UC cohort, all pts had progressed on or relapsed after a platinum-containing chemotherapy. As of Jan 10, 2021, median time from enrollment to data cutoff was 18.8 mos (range, 8.5-22.7) for RCC cohort and 7.0 mos (range, 0.9-23.6) for UC cohort. In RCC cohort, ORR was 63.2% (95% CI, 46.0-78.2; 24 PRs), DCR was 89.5% (95% CI, 75.9-95.8), median DOR was not reached (range 2-19+ mos), mPFS was not reached, and 12-mo OS rate was 88.0%. Most pts (92.1%) had reduction in target lesions, and median reduction was 47% from baseline. ORR was 84.6% (95% CI, 57.8-97.3; 11/13) for untreated RCC pts and 52.0% (95% CI, 31.3-72.2; 13/25) for pre-treated pts; DCR was 100% (95% CI, 77.2-100.0) and 84.0% (95% CI, 65.3-93.6), mPFS was not reached and 13.4 mos (95% CI: 4.1-21.0), respectively. In UC cohort, of the 33 pts with post-baseline efficacy evaluation, ORR was 33.3% (95% CI, 19.8-50.4; 1 CR, 10 PRs), DCR was 60.6% (95% CI, 43.7-75.3), median DOR was not reached (range 1.0+-16.7+ mos), mPFS was 6.4 mos (95% CI, 2.1-11.8), and mOS was not reached. ORR trended to be higher for bladder cancer (43.8%, 7/16) than upper tract urothelial carcinoma (25.0%, 4/16). Treatment-related AEs (TRAEs) occurred in 97.3% of 74 pts. Grade 3 or 4 TRAEs occurred in 63.5% of pts, mainly hypertension (23.4%), decreased platelet count (21.3%), proteinuria (17.0%), anemia (14.9%), and palmar-plantar erythrodysesthesia syndrome (14.9%). 1 pt died of TRAE (multiple organ dysfunction syndrome). Conclusions: Camrelizumab plus famitinib showed potent anti-tumor activity in pts with advanced RCC and UC with no new safety concerns. Additionally, promising ORR and durable DOR were observed in pts with heavily-treated RCC. These results support further investigation in these settings. Clinical trial information: NCT03827837.

oncology
Effectiveness and Safety of Camrelizumab in Inoperable or Advanced Non-Small Cell Lung Cancer Patients: a Multicenter Real-World Retrospective Observational Study (CTONG2004-ADV).

Si-Yang Liu,Qixun Chen,Chengzhi Zhou,Huizhong Zhang,Wen Li,Jianhua Chen,Jian Hu,Lin Wu,Qunqing Chen,Qiangsheng Dai,Jian-Zhen Shan,Fei Xu,Si-Yang Maggie Liu,Yi-Long Wu

DOI: https://doi.org/10.21037/tlcr-22-852

2023-01-01

Abstract:Background: Camrelizumab plus chemotherapy have been approved as standards for the treatment of advanced non-small cell lung cancer (NSCLC) patients based on two phase III trials. However, clinical trial results may not be representative of the general population, as clinical trials often have specific inclusion and exclusion criteria. Our research aims to investigate the real-world effectiveness and safety of camrelizumab in inoperable or advanced NSCLC patients. Methods: This multicenter retrospective observational study included inoperable or advanced pathologically confirmed NSCLC patients who received at least one dose of camrelizumab at 22 hospitals. Clinical and follow-up data of camrelizumab were collected retrospectively from the medical records. The primary outcome was the objective response rate (ORR) and secondary outcomes were disease control rate (DCR), 6-month progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (TRAEs). Multivariate logistic and Cox regression analyses were applied to identify potential predictive factors of ORR and PFS, respectively. Results: Between July 2019 and March 2021, 336 patients were included. Adenocarcinoma was seen in 58.4% and stage IV disease in 69.3%. Twenty-nine (8.6%) had liver metastasis at baseline. Most patients received camrelizumab in the first-line setting (74.1%) and in combination with chemotherapy (60.7%). The ORR was 40.2% [95% confidence interval (CI): 34.9–45.6%] and DCR was 85.1% (95% CI: 81.3–88.9%), while the 6-month PFS and OS rates were 73.0% (95% CI: 67.1–78.0%) and 93.1% (95% CI: 89.8–95.4%), respectively. In multivariate analyses, liver metastasis [odds ratio (OR), 0.324; 95% CI: 0.115–0.915; P=0.033] and increasing lines of camrelizumab treatment (vs. first line, second line: OR, 0.347; 95% CI: 0.162–0.741; P=0.006; ≥ third line: OR, 0.126; 95% CI: 0.043–0.367; P<0.001) were negatively associated, while a longer duration of camrelizumab treatment was positively associated with ORR and PFS. TRAEs were recorded in 164 (48.8%) patients, without new safety signal. Conclusions: We conducted a comprehensive overview of the effectiveness and safety profile of camrelizumab in a broader NSCLC population in real world NSCLC patients, and subgroup analysis indicated the presence of liver metastasis was associated with worse outcomes.
Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study

Lingfang Xia,Jin Peng,Ge Lou,Mei Pan,Qi Zhou,Wenjing Hu,Huirong Shi,Li Wang,Yunong Gao,Jianqing Zhu,Yu Zhang,Rong Sun,Xianfeng Zhou,Quanren Wang,Xiaohua Wu

DOI: https://doi.org/10.1136/jitc-2021-003831

IF: 12.469

2022-01-01

Journal for ImmunoTherapy of Cancer

Abstract:Background Combination treatments with immune-checkpoint inhibitor and antiangiogenic therapy have the potential for synergistic activity through modulation of the microenvironment and represent a notable therapeutic strategy in recurrent ovarian cancer (ROC). We report the results of camrelizumab (an anti-programmed cell death protein-1 antibody) in combination with famitinib (a receptor tyrosine kinase inhibitor) for the treatment of platinum-resistant ROC from an open-label, multicenter, phase 2 basket trial. Methods Eligible patients with platinum-resistant ROC were enrolled to receive camrelizumab (200 mg every 3 weeks by intravenous infusion) and oral famitinib (20 mg once daily). All patients had disease progression during or <6 months after their most recent platinum-based chemotherapy. Primary endpoint was confirmed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) V.1.1 based on investigator’s assessment. Secondary endpoints included disease control rate (DCR), duration of response (DoR), time to response (TTR), progression-free survival (PFS), overall survival (OS), 12-month OS rate and safety profile. Results Of the 37 women enrolled, 11 (29.7%) patients had primary platinum resistant, 15 (40.5%) patients had secondary platinum resistant and 11 (29.7%) patients had primary platinum refractory disease. As the cut-off date of April 9, 2021, nine (24.3%) patients had achieved a confirmed objective response, the ORR was 24.3% (95% CI, 11.8 to 41.2) and the DCR was 54.1% (95% CI, 36.9 to 70.5). Patients with this combination regimen showed a median TTR of 2.1 months (range, 1.8–4.1) and a median DoR of 4.1 months (95% CI, 1.9 to 6.3). Median PFS was 4.1 months (95% CI, 2.1 to 5.7), and median OS was 18.9 months (95% CI, 10.8 to not reached), with the median follow-up duration of 22.0 months (range, 12.0–23.7). The estimated 12-month OS rate was 67.2% (95% CI, 49.4 to 79.9). The most common ≥grade 3 treatment-related adverse events were hypertension (32.4%), decreased neutrophil count (29.7%) and decreased platelet count (13.5%). One (2.7%) patient died of grade 5 hemorrhage that was judged possibly related to study treatment by investigator. Conclusion The camrelizumab with famitinib combination appeared to show antitumor activity in heavily pretreated patients with platinum-resistant ROC with an acceptable safety profile. This combination might provide a novel alternative treatment strategy in platinum-resistant ROC setting and warranted further exploration. Trial registration number NCT03827837 .

oncology,immunology
EP11.02-04 Efficacy and Safety of Camrelizumab Plus Famitinib in Previously Treated Patients with Advanced Non Small Cell Lung Cancer

M. Gao,X. Zhang,H. Yan,Y. Zhao,D. Sun,X. Yang,Y. Ju,F. Yuan,L. Wang,H. Tao,L. Tian,C. Zhao,J. Ma,Y. Hu,Z. Liu

DOI: https://doi.org/10.1016/j.jtho.2023.09.1167

IF: 20.121

2023-01-01

Journal of Thoracic Oncology

Abstract:For non-small cell lung cancer (NSCLC) patients progressed after first-line chemotherapy, immunotherapy targeting Programmed Cell Death (Ligand) 1(PD-1/PD-L1) has shown promising activity. However, the activity is relatively limited in patients harboring Epidermal Growth Factor Receptor (EGFR) mutations and those progressed after immunotherapy. The combination of immunotherapy and anti-angiogenesis inhibitors have shown promising activity. This single-arm, phase 2 study aimed to evaluate the efficacy and safety of camrelizumab plus famitinib in previously treated patients with advanced NSCLC.
Famitinib Versus Placebo in the Treatment of Refractory Metastatic Colorectal Cancer: a Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase II Clinical Trial

Rui-Hua Xu,Lin Shen,Ke-Ming Wang,Gang Wu,Chun-Mei Shi,Ke-Feng Ding,Li-Zhu Lin,Jin-Wan Wang,Jian-Ping Xiong,Chang-Ping Wu,Jin Li,Yun-Peng Liu,Dong Wang,Yi Ba,Jue-Ping Feng,Yu-Xian Bai,Jing-Wang Bi,Li-Wen Ma,Jian Lei,Qing Yang,Hao Yu

DOI: https://doi.org/10.1186/s40880-017-0263-y

2017-01-01

Chinese Journal of Cancer

Abstract:Background Metastatic colorectal cancer (mCRC) patients with progressive disease after all available standard therapies need new medication for further treatment. Famitinib is a small-molecule multikinase inhibitor, with promising anticancer activities. This multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial was designed to evaluate the safety and efficacy of famitinib in mCRC. Methods Famitinib or placebo was administered orally once daily. The primary endpoint was progression-free survival (PFS). Secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS), quality-of-life (QoL), and safety. Results Between July 18, 2012 and Jan 22, 2014, a total of 167 patients were screened, and 154 patients were randomized in a 2:1 ratio to receive either famitinib ( n = 99) or placebo ( n = 55). The median PFS was 2.8 and 1.5 months in the famitinib and placebo groups (hazard ratio = 0.60, 95% confidence interval = 0.41–0.86, P = 0.004). The DCR was 59.8% and 31.4% ( P = 0.002) and the ORR was 2.2% and 0.0% ( P = 0.540) in the famitinib and placebo groups, respectively. The most frequent grade 3–4 adverse events were hypertension (11.1%), hand-foot syndrome (10.1%), thrombocytopenia (10.1%), and neutropenia (9.1%). Serious adverse events occurred in 11 (11.1%) patients in the famitinib group and 5 (9.1%) in the placebo group ( P = 0.788). The median OS of the famitinib and placebo groups was 7.4 and 7.2 months ( P = 0.657). Conclusion Famitinib prolonged PFS in refractory mCRC patients with acceptable tolerability. Trial registration This study was registered on ClinicalTrials.gov (NCT01762293) and was orally presented in the 2015 ASCO-Gastrointestinal Symposium
Phase I Clinical Study of FC084CSA, a High Selective AXL Kinase Inhibitor That Ameliorates Tumor Microenvironment and Augments the Effectivity of Immunotherapy.

Wei Li,Lei Wang,Jing Wang,Zhengbo Song,Qingyuan Zhang,Caicun Zhou

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.e15116

IF: 45.3

2024-01-01

Journal of Clinical Oncology

Abstract:e15116 Background: NSCLC patients with STK11 gene mutations could not benefit from immunotherapy, according to the data of multiple clinical trials. This is associated with immunosuppressive tumor microenvironment (TME) due to elevated AXL expression, and deficiency in pro-inflammatory cytokines and effector T cells. AXL inhibitor bemcentinib (formerly BGB324) has been found to improve the effectiveness of immunotherapy of immune checkpoint inhibitors. FC084CSA is a high selective AXL inhibitor. Methods: This is an ongoing first-in-human, phase I study of FC084CSA in patients with advanced solid tumors. The primary objective is to evaluate the safety and tolerability of FC084CSA. The secondary objectives include preliminary efficacy and pharmacokinetics. Results: As of January 10th, 2024, 9 patients with a median age of 60 years (44-73) were enrolled in 4 different dose levels: 100mg QD, 200mg QD, 400mg QD and 600mg QD. All patients had ≥ 2 prior lines of prior therapy. No dosing-limiting toxicities were observed. 8 (88.9%) patients experienced treatment-related adverse events (TRAEs). Most TRAEs were grade 1 or 2 and only one grade 3 TRAE was observed. The most common TRAEs (≥20%) included increased blood lactate dehydrogenase (44.4%), elevated gamma-glutamyl transferase (33.3%), proteinuria (33.3%), anemia (33.3%), increased aspartate aminotransferase (22.2%), weight loss (22.2%), increased blood creatinine (22.2%) and vomiting (22.2%). A total of 8 patients had at least 1 post-baseline tumor assessment. Objective response rate (ORR) was 0% and disease control rate (DCR) was 62.5% (5/8). Conclusions: FC084CSA was well tolerated in patients with previously heavily treated solid tumors. Clinical trial information: NCT06231550 .
43P Camrelizumab plus famitinib as first-line treatment in advanced NSCLC patients with PD-L1 TPS ≥1%: A report from a multicenter, open-label, phase II basket trial

S. Ren,X. Wang,B. Han,Y. Pan,J. Zhao,Y. Cheng,S. Hu,T. Liu,Y. Li,Y. Cheng,J. Feng,S. Yi,S. Gu,S. Gao,Y. Luo,Y. Liu,C. Liu,H. Duan,C. Zhou,J. Fan

DOI: https://doi.org/10.1016/s1556-0864(23)00297-6

IF: 20.121

2023-01-01

Journal of Thoracic Oncology

Abstract:The combination of immune-checkpoint inhibitors and antiangiogenic agents can modulate the microenvironment in a synergistic manner and represents a promising treatment option for NSCLC. The efficacy and safety of camrelizumab (an anti-PD-1 antibody) plus famitinib (a receptor tyrosine kinase inhibitor) as first-line therapy for advanced NSCLC with PD-L1 TPS ≥1% was explored in an open-label, multicenter, phase II basket trial. Eligible patients (pts) received camrelizumab (200 mg once every 3 weeks by intravenous infusion) plus oral famitinib (20 mg once daily). Primary endpoint was confirmed objective response rate (ORR) assessed by investigator per RECIST v1.1. Disease control rate (DCR), duration of response (DoR), time to response (TTR), progression-free survival (PFS), overall survival (OS), 6-, 9-, 12-month OS rates and safety profile were secondary endpoints. Among all enrolled 41 pts, 21 (51.2%) had PD-L1 TPS 1–49% and 20 (48.8%) had PD-L1 TPS ≥50% per local laboratory testing. As of data cutoff on Jun 22, 2022, 22 (53.7%) pts had achieved a confirmed objective response. This combination regimen achieved an ORR of 53.7% (95% confidence interval [CI], 37.4–69.3), and the DCR was 92.7% (95% CI, 80.1–98.5). Median DoR had not been reached yet and the median TTR was 2.1 mos (range, 1.4–8.3). With the median follow-up duration of 12.5 mos (range, 1.0–24.2), the median PFS was 16.6 mos (95% CI, 8.3-NR), median OS was 20.4 mos (95% CI, 20.4-NR; data not mature), and the estimated 12-month OS rate was 76.8% (95% CI, 60.0–87.3), respectively. The most common ≥ grade 3 treatment-related adverse events were hypertension (22.0%), increased alanine aminotransferase (12.2%) and decreased neutrophil count (9.8%). One patient (2.4%) died from grade 5 hemoptysis, which the investigator considered possibly related to the study treatment. Camrelizumab plus famitinib exhibited encouraging antitumor activity in advanced NSCLC pts whose tumor expressed PD-L1 TPS ≥1% with an acceptable safety profile. In this patient population, this combination regimen might offer an alternative treatment strategy that deserves further investigation.
840P Famitinib Malate Plus Camrelizumab for Recurrent Platinum-Resistant Ovarian/fallopian Tube/primary Peritoneal Cancer and Advanced Cervical Cancer: an Open-Label, Multicenter Phase II Study

L. Xia,Q. Zhou,Y. Zhang,Y. Gao,W. Hu,M. Pan,G. Lou,L. Wang,H. Shi,J. Zhu,H. Sun,X. Wang,Q. Wang,X. Wu

DOI: https://doi.org/10.1016/j.annonc.2020.08.979

IF: 51.769

2020-01-01

Annals of Oncology

Abstract:Famitinib malate (F) is an oral tyrosine kinase inhibitor against VEGFR-2, PDGFR, c-kit. Camrelizumab (C) is a humanised anti-PD-1 monoclonal antibody. We initiated an open-label, multicenter phase II study to assess F plus C in patients (pts) with advanced genitourinary and gynecological cancers. Herein, we report the preliminary results from the advanced cervical cancer (CC) and recurrent platinum-resistant epithelial ovarian/fallopian tube/peritoneal cancer (OC) cohorts. Pts with histologically confirmed CC that had progressed after at least one line of systemic chemotherapy for metastatic, recurrent or persistent CC or epithelial OC that had disease recurrence <6 months (mos) of last platinum-based therapy were given C 200 mg Q3W IV plus F 20 mg QD PO. Primary endpoint was the objective response rate (ORR) per RECIST v1.1. From Apr 4, 2019 to Mar 20, 2020, 19 CC pts were enrolled. Median follow-up was 10.0 mos. Of 15 pts with at least one post-baseline efficacy evaluation, Seven pts achieved confirmed partial response (PR), with two additional unconfirmed PR. The ORR was 46.7% (7/15, 95% CI 21.3-73.4) and DCR was 80.0% (12/15, 95% CI 51.9-95.7). Responses were ongoing in 6 of the 7 responders, and median duration of response (mDoR) was not reached. From Apr 19, 2019 to Mar 20, 2020, 32 OC pts were enrolled. Median follow-up was 9.3 mos. Of 31 pts with at least one post-baseline efficacy evaluation, Seven pts achieved confirmed PR, with three additional unconfirmed PR. The ORR was 22.6% (7/31, 95% CI 9.6-58.9). DCR was 61.3% (19/31, 95% CI 42.2-78.2). The mDoR was 4.1 mos. Most common grade 3-4 treatment-related AEs (TRAEs) were hypertension (17/51, 33.3%), neutropenia (12/51, 23.5%), thrombocytopenia (5/51, 9.8%), hand-foot syndrome (4/51, 7.8%), and hypertriglyceridemia (4/51, 7.8%). No pts discontinued the treatment due to TRAEs. One CC pt with recurrent pelvic lesion died due to severe vaginal bleeding. F plus C appeared to show encouraging activity in recurrent platinum-resistant OC and advanced CC with manageable safety profile, representing a novel potential treatment option that warranted further investigation.
LBA44 Camrelizumab Plus Famitinib Versus Camrelizumab Alone and Investigator’s Choice of Chemotherapy in Women with Recurrent or Metastatic Cervical Cancer

X. Wu,L. Xia,K. Zhang,Y. Tang,G. N. Zhang,D. Wang,H. Lou,N. Liu,H. Zhang,H. Chen,K. Wang,S. Wei,L. Wang,K. Gao,G. Li,Y. Hu,X. Zhou,Y. Wang,Q. Wang

DOI: https://doi.org/10.1016/j.annonc.2023.10.038

IF: 51.769

2023-01-01

Annals of Oncology

Abstract:Combining immunotherapy and anti-angiogenic agents may enhance immune response by reversing the immunosuppressive microenvironment. We conducted a randomized, open-label, phase 2 trial to assess camrelizumab (CAM, an anti-PD-1 antibody) plus famitinib (FAM, a multi-targeted TKI against VEGFR2/3) versus CAM alone and investigator's choice of chemotherapy (chemo) for recurrent or metastatic cervical cancer (R/M CC). Patients (pts) with R/M CC who failed prior platinum-based chemo were enrolled. Prior anti-PD-1/PD-L1/CTLA-4 treatment was not allowed. Pts were randomized to receive CAM 200 mg IV Q3W with (cohort A) or without (cohort B) FAM 20 mg PO QD, or investigator's choice of chemo (cohort C) every 3-week cycle. The primary endpoint was ORR per RECIST v1.1 assessed by blinded independent central review (BICR). At data cutoff on April 21, 2023, 194 pts were randomized (cohort A n=105, cohort B n=54, cohort C n=35), and 46 pts (23.7%) remained on treatment. 77.8% of pts had squamous CC, 63.9% were PD-L1 positive, 31.4% received prior targeted therapy. The median follow-up duration was 9.9 months (IQR 7.3-15.1). Antitumor activities are shown in the table. Treatment-related adverse events (TRAEs) occurred in 100%, 94.3%, and 100% of pts, respectively. Grade ≥3 TRAEs were reported in 84.8%, 15.1%, and 60.0% of pts, respectively, with the most common ones being decreased neutrophil count (23.8%, 1.9%, 30.0%), hypertension (22.9%, 0, 0), decreased white blood cell count (20.0%, 0, 33.3%), and anemia (20.0%, 1.9%, 13.3%). Dose discontinuation due to AEs occurred in 19.0%, 5.7%, and 0 pts, respectively. Treatment-related death was reported in two pts (1.9%) in cohort A (acute coronary syndrome, infection and sepsis).Table: LBA44Summary of efficacyCohort A (n=105)Cohort B (n=54)Cohort C (n=35)BICR-assessedCR9 (8.6)3 (5.6)—PR34 (32.4)10 (18.5)—ORR41.0 (31.5-51.0)24.1 (13.5-37.6)—DCR75.2 (65.9-83.1)55.6 (41.4-69.1)—PFS (mo)7.2 (6.1-12.4)4.0 (2.1-6.1)—Investigator-assessedCR4 (3.8)2 (3.7)1 (2.9)PR41 (39.0)10 (18.5)4 (11.4)ORR42.9 (33.2-52.9)22.2 (12.0-35.6)14.3 (4.8-30.3)DCR74.3 (64.8-82.3)53.7 (39.6-67.4)42.9 (26.3-60.7)PFS (mo)8.1 (6.2-12.4)4.1 (2.1-5.1)2.9 (2.0-6.2)12-months OS rate80.3 (70.7-87.0)71.9 (55.8-83.0)59.7 (40.9-74.3) Open table in a new tab CAM plus FAM showed improved antitumor activity than CAM alone or investigator's choice of chemo in pts with R/M CC, with a tolerable safety profile.
Camrelizumab Plus Carboplatin and Pemetrexed As First-Line Therapy for Advanced Non-Squamous Non-Small-cell Lung Cancer: 5-Year Outcomes of the CameL Randomized Phase 3 Study

Caicun Zhou,Gongyan Chen,Yunchao Huang,Jianying Zhou,LiZhu Lin,Jifeng Feng,Zhehai Wang,Yongqian Shu,Jianhua Shi,Yi Hu,QiMing Wang,Ying Cheng,Fengying Wu,Jianhua Chen,Xiaoyan Lin,Yongsheng Wang,Jianan Huang,Jiuwei Cui,Lejie Cao,Yunpeng Liu,Yiping Zhang,Yueyin Pan,Jun Zhao,LiPing Wang,Jianhua Chang,Qun Chen,Xiubao Ren,Wei Zhang,Yun Fan,Zhiyong He,Jian Fang,Kangsheng Gu,XiaoRong Dong,Faguang Jin,Hongjun Gao,Guangyu An,Cuimin Ding,Xiaodong Jiang,Jianping Xiong,Xiangdong Zhou,Sheng Hu,Ping Lu,Anwen Liu,Shuliang Guo,Jianjin Huang,Chengchu Zhu,Jian Zhao,Beili Gao,Yinglan Chen,Chengping Hu,Jian Zhang,Hongmei Zhang,Hui Zhao,Zhigao Wang,Xinjing Ma,Wei Shi

DOI: https://doi.org/10.1136/jitc-2024-009240

IF: 12.469

2024-01-01

Journal for ImmunoTherapy of Cancer

Abstract:BACKGROUND:CameL phase 3 study demonstrated the superiority of camrelizumab plus chemotherapy over chemotherapy alone for progression-free survival in patients with previously untreated advanced non-squamous non-small-cell lung cancer (NSCLC) without EGFR/ALK alterations. Here, we present the 5-year outcomes. METHODS:Patients were randomized (1:1) and received 4-6 cycles of camrelizumab plus carboplatin and pemetrexed (n=205) or carboplatin and pemetrexed (n=207) every 3 weeks, followed by maintenance camrelizumab plus pemetrexed or pemetrexed only. Crossover from chemotherapy group to camrelizumab monotherapy was permitted after disease progression. RESULTS:Median time from randomization to data cut-off was 65.2 months (range, 59.7-72.2). HR for overall survival (OS) was 0.74 (95% CI 0.58 to 0.93; one-sided p=0.0043), and was 0.62 (95% CI 0.49 to 0.79; one-sided p<0.0001) after adjustment for crossover. Five-year OS rates were 31.2% (95% CI 24.7% to 37.9%) with camrelizumab plus chemotherapy versus 19.3% (95% CI 13.9% to 25.3%) with chemotherapy alone. Among the 33 patients who completed 2 years of camrelizumab, 5-year OS rate was 84.3% (95% CI 66.4% to 93.2%), and 5-year duration of response rate was 46.5% (95% CI 24.9% to 65.6%) in the 32 responders. No new safety signals were noted. CONCLUSIONS:Camrelizumab plus carboplatin and pemetrexed as first-line therapy continued to demonstrate long-term OS benefit over carboplatin and pemetrexed, with manageable toxicity. Patients who completed 2 years of camrelizumab had enduring response and impressive OS. Current 5-year updated analysis further supports camrelizumab plus carboplatin and pemetrexed as a standard-of-care for previously untreated advanced non-squamous NSCLC without EGFR/ALK alterations. TRIAL REGISTRATION NUMBER:NCT03134872.
First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial

Shengxiang Ren,Xicheng Wang,Bao-Hui Han,Yueyin Pan,Jun Zhao,Yufeng Cheng,Sheng Hu,Tianshu Liu,Yalun Li,Ying Cheng,Jifeng Feng,Shanyong Yi,Shanzhi Gu,Shegan Gao,Yongzhong Luo,Ying Liu,Caigang Liu,Huijie Duan,Shuni Wang,Xinfeng Yang,Jia Fan,Caicun Zhou

DOI: https://doi.org/10.1136/jitc-2023-007227

IF: 12.469

2024-02-01

Journal for ImmunoTherapy of Cancer

Abstract:Background The combination of immune-checkpoint inhibitors and antiangiogenic agents can synergistically modulate the tumor microenvironment and represents a promising treatment option. Here, we evaluated the efficacy and safety of camrelizumab plus famitinib (a receptor tyrosine kinase inhibitor) as a first-line treatment for advanced or metastatic NSCLC patients with a programmed death ligand-1 (PD-L1) tumor proportion score (TPS) of ≥1%, in an open-label, multicenter, phase 2 basket trial. Methods Eligible patients received camrelizumab (200 mg once every 3 weeks via intravenous infusion) plus oral famitinib at an initial dose of 20 mg once daily. The primary endpoint was the objective response rate (ORR), as assessed by the investigator per Response Evaluation Criteria in Solid Tumors V.1.1. Key secondary endpoints included disease control rate (DCR), duration of respons, progression-free survival (PFS), overall survival (OS), 12-month OS rate, and safety profile. Results Of the enrolled 41 patients, 21 (51.2%) had a PD-L1 TPS of 1–49%. As of the cut-off date on June 22, 2022, the combination regimen of camrelizumab and famitinib achieved an ORR of 53.7% (95% CI 37.4% to 69.3%) and a DCR of 92.7% (95% CI 80.1% to 98.5%). The median PFS was 16.6 months (95% CI 8.3 to not reached), and OS data were not yet mature, with an estimated 12-month OS rate of 76.8% (95% CI 60.0% to 87.3%). The most common treatment-related adverse events of grade 3 or higher included hypertension (22.0%), increased alanine aminotransferase (12.2%), decreased neutrophil count (9.8%), proteinuria (7.3%), decrease platelet count (7.3%), and hypokalemia (7.3%). One (2.4%) patient died from grade 5 hemoptysis, which was considered possibly related to the study treatment by the investigator. Conclusion Camrelizumab plus famitinib demonstrated promising antitumor activity in advanced or metastatic NSCLC patients and had an acceptable safety profile. These findings suggest that this combination regimen could be an alternative therapeutic option and warrant further investigation. Trial registration number NCT04346381 .

oncology,immunology
Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma: Data from an open-label, multicenter phase II basket study.

Ming-Yuan Chen,Xiaozhong Chen,Ximei Zhang,Tianshu Liu,Xicheng Wang,Jinling Cai,Shuni Wang,Chunxia Chen,Jia Fan

DOI: https://doi.org/10.1200/jco.2022.40.16_suppl.e18031

IF: 45.3

2022-06-01

Journal of Clinical Oncology

Abstract:e18031 Background: Immune-checkpoint inhibitor (ICI) in combination with antiangiogenic therapy have the potential for synergistic activity. We report the results of camrelizumab plus famitinib for the treatment of recurrent or metastatic, ICI-resistant nasopharyngeal carcinoma (NPC) from an open-label, multicenter, phase II basket trial. Methods: Patients (pts) with histologically confirmed recurrent or metastatic NPC (nonkeratinizing carcinoma, WHO type II-III), who had been treated with platinum-based chemotherapy and ICIs (≤2 lines of systemic treatment), were enrolled to receive camrelizumab (200 mg intravenously every 3 weeks) and famitinib (20 mg orally once daily). Primary endpoint was objective response rate (ORR) per RECIST version 1.1, and secondary endpoints included duration of response (DoR), disease control rate (DCR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and safety. Results: Between Oct 23, 2020, and Sep 24, 2021, 15 recurrent or metastatic NPC pts were enrolled. Among them, 12 (80.0%) and 3 (20.0%) pts had received their prior 1st-line and 2nd-line treatment, respectively. All pts were pretreated with anti-PD-1/PD-L1 immunotherapy (toripalimab, n = 9; tislelizumab, n = 4; sintilimab, n = 1; pembrolizumab, n = 1). As of Nov 30, 2021, median time from enrollment to data cutoff was 6.3 months (range, 2.2-13.3). No pt had a complete response, 5 (33.3%) pts had a confirmed partial response, 7 (46.7%) pts had stable disease, 2 (13.3%) pts had progressive disease and 1 (6.7%) pt was not evaluable. The ORR was 33.3% (95% confidence interval [CI], 11.8-61.6), the DCR was 80.0% (95% CI, 51.9-95.7). Most pts (73.3%) experienced reduction in target lesion size from baseline, with a median change of -36.0%. The median DoR was 4.2 months (95% CI, 2.1-not reached [NR]), median PFS was 6.3 months (95% CI, 4.1-NR), and median OS has not been reached. Treatment-related adverse events (TRAEs) of grade 3 or higher were reported in 7 (46.7%) pts, mainly decreased platelet count (13.3%), decreased neutrophil count (13.3%) and palmar-plantar erythrodysaesthesia syndrome (13.3%). Treatment interruption and discontinuation due to TRAEs occurred in 11 (73.3%) and 1 (6.7%) pts, respectively. Five (33.3%) pts had serious TRAEs (grade 2 platelet count decreased, grade 2 pharyngeal necrosis, grade 2 pulmonary tuberculosis, grade 3 left ventricular dysfunction, grade 3 pharyngeal hemorrhage; n = 1 for each), and no treatment-related death was reported. Conclusions: Camrelizumab plus famitinib showed encouraging antitumor activity in recurrent or metastatic NPC patients who were resistant to ICI treatment, with an acceptable and manageable safety profile. This combination might provide a novel alternative treatment strategy in this challenging disease setting and support further investigation. Clinical trial information: NCT04346381.

oncology

Table S1 from Camrelizumab Plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study

Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study

Camrelizumab plus famitinib in patients with metastatic colorectal cancer: Results from an open-label, multicenter phase II basket study.

Camrelizumab Plus Famitinib Malate in Patients with Advanced Renal Cell Cancer and Unresectable Urothelial Carcinoma: A Multicenter, Open-Label, Single-Arm, Phase II Trial.

Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study

Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter, Phase Ii Clinical Study of Famitinib in the Treatment of Advanced Metastatic Colorectal Cancer

A Multicenter Phase 2 Trial of Camrelizumab Plus Famitinib for Women with Recurrent or Metastatic Cervical Squamous Cell Carcinoma.

Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A for Nonrandomized, Open-label, Phase II Trial

Camrelizumab plus famitinib for advanced renal cell carcinoma or unresectable urothelial carcinoma: Updated results from a phase II trial.

Effectiveness and Safety of Camrelizumab in Inoperable or Advanced Non-Small Cell Lung Cancer Patients: a Multicenter Real-World Retrospective Observational Study (CTONG2004-ADV).

Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study

EP11.02-04 Efficacy and Safety of Camrelizumab Plus Famitinib in Previously Treated Patients with Advanced Non Small Cell Lung Cancer

Famitinib Versus Placebo in the Treatment of Refractory Metastatic Colorectal Cancer: a Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase II Clinical Trial

Phase I Clinical Study of FC084CSA, a High Selective AXL Kinase Inhibitor That Ameliorates Tumor Microenvironment and Augments the Effectivity of Immunotherapy.

43P Camrelizumab plus famitinib as first-line treatment in advanced NSCLC patients with PD-L1 TPS ≥1%: A report from a multicenter, open-label, phase II basket trial

840P Famitinib Malate Plus Camrelizumab for Recurrent Platinum-Resistant Ovarian/fallopian Tube/primary Peritoneal Cancer and Advanced Cervical Cancer: an Open-Label, Multicenter Phase II Study

LBA44 Camrelizumab Plus Famitinib Versus Camrelizumab Alone and Investigator’s Choice of Chemotherapy in Women with Recurrent or Metastatic Cervical Cancer

Camrelizumab Plus Carboplatin and Pemetrexed As First-Line Therapy for Advanced Non-Squamous Non-Small-cell Lung Cancer: 5-Year Outcomes of the CameL Randomized Phase 3 Study

First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial

Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma: Data from an open-label, multicenter phase II basket study.